The first clinical trial of the nephroprotective effect of albumin infusion was achieved in patients with severe hypoalbuminemia, decompensated liver cirrhosis, and diuretic-induced fully reversible kidney injury [74]. This evidence concerns the gene ALB and cirrhosis of liver.